Oruka Therapeutics, Inc.
Financials
Valuation Metrics
Oruka Therapeutics, Inc.'s Market Cap is $6.32B. At end of 2025 it was $1.65B. Ranked #1157 of 3,118 in US market (top 37%), #376 of 1,474 on NASDAQ (top 26%), #63 of 265 in Pharmaceuticals, Biotechnology & Life Sciences (top 24%) by Market Cap.
Investment Metrics(as of 2026-11-02)
| Metric | Value | Rank |
|---|---|---|
| Size | ||
| Market Cap | $6.32B | US#1,157/3,118 Sec#63/265 |
| Revenue | $0.00 | US#2,858/3,118 Sec#193/265 |
| Net Income | $-133M | US—/3,118 Sec—/265 |
| Total Assets | $1.14B | US#2,406/3,118 Sec#91/265 |
| Net Assets | $1.11B | US#1,686/3,118 Sec#57/265 |
| Employees | 68 | US#2,663/3,118 Sec#195/265 |
| Value | ||
| P/B | 5.67x | US#2,327/3,118 Sec#155/265 |
| FCF Yield | -1.60% | US—/3,118 Sec—/265 |
| Profitability | ||
| ROE | -11.92% | US#2,388/3,118 Sec#85/265 |
| ROA | -11.66% | US#2,682/3,118 Sec#107/265 |
| Financial Health | ||
| Debt Ratio | 2.23% | US#23/3,118 Sec#5/265 |
| Total Debt | $3M | US#2,934/3,118 Sec#230/265 |
| FCF | $-101M | US#2,630/3,118 Sec#145/265 |
| Cash | $268M | US#1,495/3,118 Sec#90/265 |
| Current Ratio | 38.51x | US#64/3,118 Sec#6/265 |
| Performance | ||
| 1Y Return | 238.98% | US#24/3,118 Sec#10/265 |
| 1M Return | 12.98% | US#360/3,118 Sec#23/265 |
| From 52W High | -17.34% | US#1,247/3,118 Sec#66/265 |
| 1Y MDD | -36.39% | US#1,729/3,118 Sec#97/265 |
| Trading | ||
| Volume | 551,763 shares | US#1,936/3,118 Sec#189/265 |
| Trading Value | $53M | US#1,210/3,118 Sec#71/265 |
| Per Share | ||
| EPS | $-2.01 | US—/3,118 Sec—/265 |
| BPS | $16.83 | US#1,417/3,118 Sec#45/265 |
Company Info
Oruka Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing novel monoclonal antibody therapeutics for psoriasis (PsO), and other inflammatory and immunology (I&I) indications. Its lead products include ORKA-001 that targets p19 subunit of interleukin-23, which is in phase 2a trial for the treatment of PsO; and ORKA-002 that targets interleukin-17A and interleukin-17F, which is in phase 2 trial for the treatment of PsO, psoriatic arthritis, and other conditions. The company also develops ORKA-003 for targeting an undisclosed pathway; and ORKA-021, a sequential combination regimen of ORKA-002 and ORKA-001. Oruka Therapeutics, Inc. is headquartered in Menlo Park, California.